The cytokine theory of depression no longer brings about any doubts. Experiments and
research studies conducted in the last ten years have confirmed that both physical and …

Objectives: The overview outlines two decades of research from the European Group for the
Study of Resistant Depression (GSRD) that fundamentally impacted evidence-based …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Objectives Clinical variables were investigated in the 'treatment resistant depression (TRD)‐
III'sample to replicate earlier findings by the European research consortium 'Group for the …

Background Clear guidance for successive antidepressant pharmacological treatments for
non-responders in major depression is not well established. Method Based on the …

Background Individuals with major depressive disorder (MDD) are at higher risk for obesity.
In turn, weight gain is a predisposing factor for depression. Although clinical data are sparse …

Monoamine oxidase inhibitors (MAOIs) were among the first licensed pharmacological
treatments for patients with depression but over time have fallen out of mainstream clinical …

Depression and Obstructive sleep apnea (OSA) are the major associated comorbidities.
OSA is a rapidly growing problem in the society that is connected to the rising rates of …

Background Women are nearly twice as likely as men to suffer from major depressive
disorder. Yet, there is a dearth of studies comparing the clinical outcomes of women and …

Background Subanesthetic ketamine has accumulated meta-analytic evidence for rapid
antidepressant effects in treatment-resistant depression (TRD), resulting in both excitement …